Global Treatment For Neglected Tropical Disease Market Set To Grow To $3.0bn By 2022

10 August 2018
Pharma

Visiongain has launched a new pharma report Global Treatment for Neglected Tropical Disease Market 2017-2027: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease

According to the Centers for Disease Control and Prevention (CDC), one hundred percent of low-income countries are affected by at least five neglected tropical diseases simultaneously. Worldwide, 149 countries and territories are affected by at least one neglected tropical disease (NTD). The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travellers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed.

The lead analyst of the report commented “The treatment for neglected tropical disease market is set to experience considerable growth over the next decade. The main growth drivers include, rising awareness towards neglected tropical disease, increasing prevalence of neglected disease such as malaria and dengue as well as increasing governments’ initiatives.

There are still gaps that need to be met. Improved diagnostics for neglected tropical diseases for example, are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.”

Leading companies featured in the report include Pfizer, Inc., Bayer, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd, Sanofi S.A. and Eisai Co., Ltd.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Visiongain Publishes Behavioural Health Market Report to 2031

The global behavioural Health market has been growing considerably owing to the rising pressure/stress at work, growing incidence and prevalence rate of depression and PTSD (Post Traumatic Stress Disorder) around the globe.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever